Hydroxychloroquine is a medication commonly used to treat malaria and certain autoimmune conditions. In this trial, it is being studied as a treatment for pulmonary sarcoidosis (a condition affecting the lungs). It works by reducing inflammation and modifying the body’s immune response.

Corticosteroids are anti-inflammatory medications that help reduce inflammation and suppress the immune system. In this trial, they are being tested at different doses in combination with hydroxychloroquine to treat pulmonary sarcoidosis. Corticosteroids are commonly used as a standard treatment for sarcoidosis to help improve breathing and reduce inflammation in the lungs.

Sarcoidosis – A rare inflammatory disease that causes small clumps of cells called granulomas to form in various organs of the body. It most commonly affects the lungs and lymph nodes, but can also develop in the eyes, skin, heart, and other organs. The condition typically starts in the lungs, where the granulomas can cause inflammation and change the normal structure of the tissue. Sarcoidosis can develop gradually and may cause symptoms such as shortness of breath, persistent dry cough, fatigue, and chest pain. In some cases, the condition may not cause any noticeable symptoms and can be discovered accidentally during chest X-rays performed for other reasons. The disease can affect people of any age, but it most commonly develops between the ages of 20 and 40.